ATS GUIDELINES Bundle

Drug-Resistant Tuberculosis

American Thoracic Society Quick-Reference GUIDELINES Apps

Issue link: http://eguideline.guidelinecentral.com/i/1206585

Contents of this Issue

Navigation

Page 15 of 15

Disclaimer is pocket guide attempts to define principles of practice that should produce high-quality patient care. It is applicable to specialists, primary care, and providers at all levels. is pocket guide should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. e ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aer consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool. e guideline provides evidence-based recommendations that have been developed using GR ADE (Grading of Recommendations, Assessment, Development, and Evaluation) methodolog y. GR ADE involves structured literature review, systematic reviews and meta-analyses of combined data, and expert discussion to assess the certainty in the evidence and determine the strength of each recommendation. Source Nahid P, Mase S, Battista G, et al. Treatment of Drug-Resistant Tuberculosis Am J Respir Crit Care Med. 2019;200(10):pp e93–e142. e guideline was a cooperative effort among the American oracic Society, the United States Centers for Disease Control and Prevention, the European Respiratory Society, and the Infectious Diseases Society of America. 106 Commerce Street, Suite 105 Lake Mary, FL 32746 TEL: 407.878.7606 • FAX: 407.878.7611 Order additional copies at GuidelineCentral.com Copyright © 2020 All rights reserved ATSMDRTB01202a Abbreviations ATS, American oracic Society; CDC, Center for Disease Control and Prevention; DR-TB, drug-resistant TB; DST, drug susceptibility test; ERS, European Respiratory Society; IDSA, Infectious Diseases Society of America; IM, intramuscular; IPDMA, Individual Patient/Participant Data Meta-Analysis; IV, intravenous; MDR-TB, multiple drug-resistant TB; PO, oral; pre-XDR-TB, pre-extensively drug-resistant TB; TDM, erapeutic Drug Monitoring ; TB, tuberculosis; XDR-TB, extensively drug-resistant TB; WHO, World Health Organization

Articles in this issue

Links on this page

view archives of ATS GUIDELINES Bundle - Drug-Resistant Tuberculosis